Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erythropoietin alpha - Dong-A ST

Next Previous
X
Search
Drug Profile

Erythropoietin alpha - Dong-A ST

Alternative Names: DA-3285; EPO - Dong-A ST; Eporon; Erythropoietin - Dong-A; Erythropoietin alfa

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dem Ilac; Dong-A Pharmaceutical
  • Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Ischaemia

Most Recent Events

  • 28 Sep 2022 Discontinued - Phase-II for Ischaemia in South Korea (IV) (Dong-A Pharmaceutical pipeline, September 2022)
  • 15 Jul 2016 Phase-II clinical trials in Ischaemia in South Korea (IV) (NCT02603406)
  • 03 Feb 2016 Dong-A ST and Ajou University School of Medicine plan the phase II NIMBUS trial for Stroke in South Korea (IV) (NCT02603406)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top